Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer

NCT07771764 is registered in ClinicalTrials.gov with First Affiliated Hospital of Fujian Medical University as lead sponsor.

NCT NCT07771764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07771764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
December 1, 2030
Enrollment
30 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive non small cell lung cancer